Optimizing Follow-up Assessment of Patients with Cutaneous Melanoma

Annals of Surgical Oncology

Volumn 24, Issue 4, 2017, Pages 861-863

  Bhutiani, Neal ^a   Egger, Michael E ^b   McMasters, Kelly M ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOTHERAPY; LUNG METASTASIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; RISK ASSESSMENT; SENTINEL LYMPH NODE; SURVIVAL RATE; AFTERCARE; MELANOMA; PROCEDURES; SKIN TUMOR; STANDARDS;

AFTERCARE; FOLLOW-UP STUDIES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 85010755893     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-017-5771-0     Document Type: Editorial

References (6)

1. National Comprehensive Cancer Network (NCCN). In: NCCN clinical practice guidelines in oncology. 2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 15 Dec 2016.
2. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042.
3. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, AJCC Melanoma Task Force. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17:2006–14.
4. Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin RC II, Schacherer CW, et al. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012;214:608–17.
5. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175–83. doi:10.1158/1078-0432.CCR-13-3316.
6. Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780–5.e3.